Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression

International Journal of Oncology

Volumn 14, Issue 4, 1999, Pages 771-776

  Wan, Yonghong ^a   Emtage, Peter ^a   Foley, Ronan ^a   Carter, Ronald ^a   Gauldie, Jack ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus; Breast cancer; Dendritic cells; Humoral immunity; Tumor vaccination

Indexed keywords

TUMOR ANTIGEN;

ADENOVIRUS; ANIMAL; ARTICLE; BIOSYNTHESIS; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; FEMALE; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; LIVER; LUNG TUMOR; METASTASIS; MOUSE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNIZATION; IMMUNOTHERAPY; LIVER; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM METASTASIS; TRANSDUCTION, GENETIC;

EID: 0033113957     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.4.771     Document Type: Article

References (26)

1. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J and Graham FJ: Intratumoral injection of an adenovirus vector expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 92: 8522-8526, 1995.
2. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J and Graham FJ: Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 7: 1995-2002, 1996.
3. Emtage PCR, Wan Y, Bramson JL, Graham FL and Gauldie J: A double recombinant adenovirus expressing the costimulatory molecule B7-1 (Murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J Immunol 160: 2531-2538, 1998.
4. Chen PY, Wang M, Bronte V, Zhai Y, Rosenberg SA and Restifo NP: Therapeutic anti-tumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156: 225-231, 1996.
5. Zhai Y, Yang JC, Kawakami Y, Spiess P, Wadsworth SC, Cardoza LM, Couture LA, Smith AE and Rosenburg SA: Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol 156: 700-710, 1996.
6. Yang Y, Nunes FA, Berensci K, Furth E, Gonczol E and Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411, 1994.
7. Yang Y, Li Q, Ertl HCJ and Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004-2015, 1995.
8. Dai Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnick N and Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92: 1401-1405, 1995.
9. Yang Y, Ertl HCJ and Wilson JM: MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1: 433-442, 1994.
10. Bramson JL, Hitt M, Gauldie J and Graham FL: Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4: 1069-1076, 1997.
11. Wan Y, Bramson JL, Carter R, Graham FL and Gauldie J: Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 8: 1355-1363, 1997.
12. Gahery-Segard H, Juillard V, Gaston J, Lengagne R, Pavirani A, Boulanger P and Guillet JG: Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. Eur J Immunol 27: 653-659, 1997.
13. Kolls JK, Lei D, Odom G, Nelson S, Summer WR, Gerber MA and Shllito JE: Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 7: 489-497, 1996.
14. Smith TAG, White BD, Gardner JM, Kaleko M and McClelland A: Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 3: 496-502, 1996.
15. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA and Wilson JM: Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 70: 6370-6377, 1996.
16. Schowalter DB, Meuse L, Wilson CB, Linsley PS and Kay MA: Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression. Gene Ther 4: 853-860, 1997.
17. Guerette B, Vilquin JT, Gingras M, Gravel C, Wood KJ and Tremblay JP: Prevention of immune reactions by first generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum Gene Ther 7: 1455-1463, 1996.
18. Guy CT, Cardiff RD and Muller WJ: Induction of mammary tumors by expression of polyoma middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12: 954-961, 1992.
19. Davidson D and Hassell JA: Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector. J Virol 61: 1226-1239, 1987.
20. Andrews DW, Gupta J and Abisdris G: Evidence that the middle T antigen of polyomavirus interacts with the membrane skeleton. Mol Cell Biol 13: 4703-4713, 1993.
21. Addison CL, Hitt M, Kunskcn D and Graham FL: Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 78: 1653-1661, 1997.
22. Hitt M, Bett AJ, Prevec L and Graham FL: Construction and propagation of human adenovirus vectors. In: Cell Biology: A Laboratory Handbook. Celis JE (ed.) Academic Press, San Diego, pp500-512, 1998.
23. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C and Dichek DA: Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. J Clin Invest 99: 209-219, 1997.
24. Gahery-Segard H, Molinier-Frenkel V, Boulaire CL, Saulnier P, Opolon P, Lengagne R, Gautier E, Cesne AL, Zitvogel L, Venet A, Schatz C, Courtney M, Chevalier TL, Tursz T, Guillet JG and Farace F: Phase I trial of recombinant adenovirus gene transfer in lung cancer: longitudinal study of the immune responses to transgene and viral products. J Clin Invest 100: 2218-2226, 1997.
25. Brossart P, Goldrath AW, Butz BE, Martin S and Bevan MJ: Virus-mediated delivery of antigenic epitopes into dendritic cells as a mean to induce CTL. J Immunol 158: 3270-3276, 1997.
26. DeMatteo R, Chu G, Ahn M, Chang E, Burke C, Raper SE, Barker CF and Markmann JF: Immunologic barriers to hepatic adenoviral gene therapy for transplantation: cellular and humoral responses limit transgene expression in mouse liver. Transplantation 63: 315-319, 1997.